|
1
|
Li S, Keenan JI, Shaw IC and Frizelle FA:
Could microplastics be a driver for early onset colorectal cancer?
Cancers (Basel). 15(3323)2023.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Matich EK, Laryea JA, Seely KA, Stahr S,
Su LJ and Hsu PC: Association between pesticide exposure and
colorectal cancer risk and incidence: A systematic review.
Ecotoxicol Environ Saf. 219(112327)2021.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Pritchett N, Spangler EC, Gray GM,
Livinski AA, Sampson JN, Dawsey SM and Jones RR: Exposure to
outdoor particulate matter air pollution and risk of
gastrointestinal cancers in adults: A Systematic review and
meta-analysis of epidemiologic evidence. Environ Health Perspect.
130(36001)2022.PubMed/NCBI View
Article : Google Scholar
|
|
4
|
Picetti R, Deeney M, Pastorino S, Miller
MR, Shah A, Leon DA, Dangour AD and Green R: Nitrate and nitrite
contamination in drinking water and cancer risk: A systematic
review with meta-analysis. Environ Res. 210(112988)2022.PubMed/NCBI View Article : Google Scholar
|
|
5
|
González N, Marquès M, Nadal M and Domingo
JL: Meat consumption: Which are the current global risks? A review
of recent (2010-2020) evidences. Food Res Int.
137(109341)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
García-Pérez J, Fernández de Larrea-Baz N,
Lope V, Molina AJ, O'Callaghan-Gordo C, Alonso MH, Rodríguez-Suárez
MM, Mirón-Pozo B, Alguacil J, Gómez-Acebo I, et al: Residential
proximity to industrial pollution sources and colorectal cancer
risk: A multicase-control study (MCC-Spain). Environ Int.
144(106055)2020.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lotfollahzadeh S, Recio-Boiles A and Cagir
B: Colon cancer. In: StatPearls [Internet].StatPearls Publishing,
Treasure Island, FL, 2023.
|
|
8
|
US Preventive Services Task Force.
Davidson KW, Barry MJ, Mangione CM, Cabana M, Caughey AB, Davis EM,
Donahue KE, Doubeni CA, Krist AH, et al: Screening for colorectal
cancer: US Preventive services task force recommendation statement.
JAMA. 325:1965–1977. 2021.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Kahi CJ, Hewett DG, Norton DL, Eckert GJ
and Rex DK: Prevalence and variable detection of proximal colon
serrated polyps during screening colonoscopy. Clin Gastroenterol
Hepatol. 9:42–46. 2011.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Steele SR, Johnson EK, Champagne B, Davis
B, Lee S, Rivadeneira D, Ross H, Hayden DA and Maykel JA: Endoscopy
and polyps-diagnostic and therapeutic advances in management. World
J Gastroenterol. 19:4277–4288. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Quintero E, Castells A, Bujanda L,
Cubiella J, Salas D, Lanas Á, Andreu M, Carballo F, Morillas JD,
Hernández C, et al: Colonoscopy versus fecal immunochemical testing
in colorectal-cancer screening. N Engl J Med. 366:697–706.
2012.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: . Global Cancer Statistics
2020: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 71:209–249.
2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Li P, Li S, Chen J, Shao L, Lu X and Cai
J: Association between family history and prognosis of patients
with colorectal cancer: A systematic review and meta-analysis.
Transl Cancer Res. 11:124–133. 2022.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Wautier JL and Wautier MP: Old and new
blood markers in human colorectal cancer. Int J Mol Sci.
23(12968)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Siegel RL, Fedewa SA, Anderson WF, Miller
KD, Ma J, Rosenberg PS and Jemal A: Colorectal cancer incidence
patterns in the United States, 1974-2013. J Natl Cancer Inst.
109(djw322)2017.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Doubeni CA, Corley DA, Quinn VP, Jensen
CD, Zauber AG, Goodman M, Johnson JR, Mehta SJ, Becerra TA, Zhao
WK, et al: Effectiveness of screening colonoscopy in reducing the
risk of death from right and left colon cancer: A large
community-based study. Gut. 67:291–298. 2018.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Cappell MS: The pathophysiology, clinical
presentation, and diagnosis of colon cancer and adenomatous polyps.
Med Clin North Am. 89:1–42, vii. 2005.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Nagtegaal ID, Odze RD, Klimstra D, Paradis
V, Rugge M, Schirmacher P, Washington KM, Carneiro F and Cree IA:
WHO Classification of Tumours Editorial Board. The 2019 WHO
classification of tumours of the digestive system. Histopathology.
76:182–188. 2019.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Shah SC and Itzkowitz SH: Colorectal
cancer in inflammatory bowel disease: Mechanisms and management.
Gastroenterology. 162:715–730.e3. 2022.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Jung G, Hernández-Illán E, Moreira L,
Balaguer F and Goel A: Epigenetics of colorectal cancer: Biomarker
and therapeutic potential. Nature reviews. Nat Rev Gastroenterol
Hepatol. 17:111–130. 2020.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Lao VV and Grady WM: Epigenetics and
colorectal cancer. Nat Rev Gastroenterol Hepatol. 8:686–700.
2011.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Cervena K, Siskova A, Buchler T, Vodicka P
and Vymetalkova V: Methylation-Based therapies for colorectal
cancer. Cells. 9(1540)2020.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Jass JR, Baker K, Zlobec I, Higuchi T,
Barker M, Buchanan D and Young J: Advanced colorectal polyps with
the molecular and morphological features of serrated polyps and
adenomas: Concept of a ‘fusion’ pathway to colorectal cancer.
Histopathology. 49:121–131. 2006.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Ogino S, Kawasaki T, Kirkner GJ, Suemoto
Y, Meyerhardt JA and Fuchs CS: Molecular correlates with MGMT
promoter methylation and silencing support CpG island methylator
phenotype-low (CIMP-low) in colorectal cancer. Gut. 56:1564–1571.
2007.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Weisenberger DJ, Levine AJ, Long TI,
Buchanan DD, Walters R, Clendenning M, Rosty C, Joshi AD, Stern MC,
LeMarchand L, et al: Association of the colorectal CpG island
methylator phenotype with molecular features, risk factors, and
family history. Cancer Epidemiol Biomarkers Prev. 24:512–519.
2015.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Imperiale TF, Ransohoff DF and Itzkowitz
SH: Multitarget stool DNA testing for colorectal-cancer screening.
N Engl J Med. 371:187–188. 2014.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Kadiyska T and Nossikoff A: Stool DNA
methylation assays in colorectal cancer screening. World J
Gastroenterol. 21:10057–10061. 2015.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Tahara T, Yamamoto E, Madireddi P, Suzuki
H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T,
et al: Colorectal carcinomas with CpG island methylator phenotype 1
frequently contain mutations in chromatin regulators.
Gastroenterology. 146:530–538.e5. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Toyota M, Ahuja N, Ohe-Toyota M, Herman
JG, Baylin SB and Issa JP: CpG island methylator phenotype in
colorectal cancer. Proc Natl Acad Sci USA. 96:8681–8686.
1999.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Weisenberger DJ, Siegmund KD, Campan M,
Young J, Long TI, Faasse MA, Kang GH, Widschwendter M, Weener D,
Buchanan D, et al: CpG island methylator phenotype underlies
sporadic microsatellite instability and is tightly associated with
BRAF mutation in colorectal cancer. Nat Genet. 38:787–793.
2006.PubMed/NCBI View
Article : Google Scholar
|
|
31
|
Snover DC: Update on the serrated pathway
to colorectal carcinoma. Hum Pathol. 42:1–10. 2011.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Nakanishi Y, Diaz-Meco MT and Moscat J:
Serrated colorectal cancer: The road less travelled? Trends Cancer.
5:742–754. 2019.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Missiaglia E, Jacobs B, D'Ario G, Di Narzo
AF, Soneson C, Budinska E, Popovici V, Vecchione L, Gerster S, Yan
P, et al: Distal and proximal colon cancers differ in terms of
molecular, pathological, and clinical features. Ann Oncol.
25:1995–2001. 2014.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Tran B, Kopetz S, Tie J, Gibbs P, Jiang
ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O and Desai J: Impact of
BRAF mutation and microsatellite instability on the pattern of
metastatic spread and prognosis in metastatic colorectal cancer.
Cancer. 117:4623–4632. 2011.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Pino MS and Chung DC: The chromosomal
instability pathway in colon cancer. Gastroenterology.
138:2059–2072. 2010.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Lengauer C, Kinzler KW and Vogelstein B:
Genetic instabilities in human cancers. Nature. 396:643–649.
1998.PubMed/NCBI View
Article : Google Scholar
|
|
37
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Grady WM and Carethers JM: Genomic and
epigenetic instability in colorectal cancer pathogenesis.
Gastroenterology. 135:1079–1099. 2008.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Jass JR, Whitehall VL, Young J and Leggett
BA: Emerging concepts in colorectal neoplasia. Gastroenterology.
123:862–876. 2002.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Fodde R, Kuipers J, Rosenberg C, Smits R,
Kielman M, Gaspar C, van Es JH, Breukel C, Wiegant J, Giles RH and
Clevers H: Mutations in the APC tumour suppressor gene cause
chromosomal instability. Nat Cell Biol. 3:433–438. 2001.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Sparks AB, Morin PJ, Vogelstein B and
Kinzler KW: Mutational analysis of the APC/beta-catenin/Tcf pathway
in colorectal cancer. Cancer Res. 58:1130–1134. 1998.PubMed/NCBI
|
|
42
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Futreal. Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Jass JR: Classification of colorectal
cancer based on correlation of clinical, morphological and
molecular features. Histopathology. 50:113–130. 2007.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Rex DK, Ahnen DJ, Baron JA, Batts KP,
Burke CA, Burt RW, Goldblum JR, Guillem JG, Kahi CJ, Kalady MF, et
al: Serrated lesions of the colorectum: Review and recommendations
from an expert panel. Am J Gastroenterol. 107:1315–1329; quiz 1314,
1330. 2012.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Zygulska AL and Pierzchalski P: Novel
diagnostic biomarkers in colorectal cancer. Int J Mol Sci.
23(852)2022.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Zhong J, Ding S, Zhang X, Di W, Wang X,
Zhang H, Chen Y, Zhang Y and Hu Y: To investigate the occurrence
and development of colorectal cancer based on the PI3K/AKT/mTOR
signaling pathway. Front Biosci (Landmark Ed).
28(37)2023.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Nusse R and Clevers H: Wnt/β-Catenin
signaling, disease, and emerging therapeutic modalities. Cell.
169:985–999. 2017.PubMed/NCBI View Article : Google Scholar
|
|
48
|
Vermeulen L, De Sousa E, Melo F, van der
Heijden M, Cameron K, de Jong JH, Borovski T, Tuynman JB, Todaro M,
Merz C, Rodermond H, et al: Wnt activity defines colon cancer stem
cells and is regulated by the microenvironment. Nat Cell Biol.
12:468–476. 2010.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Söreide K, Janssen EA, Söiland H, Körner H
and Baak JP: Microsatellite instability in colorectal cancer. Br J
Surg. 93:395–406. 2006.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Odoux C, Fohrer H, Hoppo T, Guzik L, Stolz
DB, Lewis DW, Gollin SM, Gamblin TC, Geller DA and Lagasse E: A
stochastic model for cancer stem cell origin in metastatic colon
cancer. Cancer Res. 68:6932–6941. 2008.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Kandoth C, McLellan MD, Vandin F, Ye K,
Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA, et al:
Mutational landscape and significance across 12 major cancer types.
Nature. 502:333–339. 2013.PubMed/NCBI View Article : Google Scholar
|
|
52
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2002.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Jaiswal S: Clonal hematopoiesis and
nonhematologic disorders. Blood. 136:1606–1614. 2020.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Jaiswal S and Ebert BL: Clonal
hematopoiesis in human aging and disease. Science.
366(eaan4673)2019.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Haggar FA and Boushey RP: Colorectal
cancer epidemiology: Incidence, mortality, survival, and risk
factors. Clin Colon Rectal Surg. 22:191–197. 2009.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Yoda A, Adelmant G, Tamburini J, Chapuy B,
Shindoh N, Yoda Y, Weigert O, Kopp N, Wu SC, Kim SS, et al:
Mutations in G protein β subunits promote transformation and kinase
inhibitor resistance. Nat Med. 21:71–75. 2015.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Kosianova А, Pak O and Bryukhovetskiy I:
Regulation of cancer stem cells and immunotherapy of glioblastoma
(Review). Biomed Rep. 20(24)2023.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Bryukhovetskiy I, Kosianova A, Zaitsev S,
Pak O, Sharma A and Sharma HS: Glioblastoma: What can we do for
these patients today and what will we be able to do in the future?
Prog Brain Res. 265:99–118. 2021.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Pinczowski D, Ekbom A, Baron J, Yuen J and
Adami HO: Risk factors for colorectal cancer in patients with
ulcerative colitis: A case-control study. Gastroenterology.
107:117–120. 1994.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Qiu X, Ma J, Wang K and Zhang H:
Chemopreventive effects of 5-aminosalicylic acid on inflammatory
bowel disease-associated colorectal cancer and dysplasia: A
systematic review with meta-analysis. Oncotarget. 8:1031–1045.
2017.PubMed/NCBI View Article : Google Scholar
|
|
61
|
OʼConnor A, Packey CD, Akbari M and Moss
AC: Mesalamine, but not sulfasalazine, reduces the risk of
colorectal neoplasia in patients with inflammatory bowel disease:
An agent-specific systematic review and meta-analysis. Inflamm
Bowel Dis. 21:2562–2569. 2015.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Lyakhovich A and Gasche C: Systematic
review: Molecular chemoprevention of colorectal malignancy by
mesalazine. Aliment Pharmacol Ther. 31:202–209. 2010.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Luciani MG, Campregher C, Fortune JM,
Kunkel TA and Gasche C: 5-ASA affects cell cycle progression in
colorectal cells by reversibly activating a replication checkpoint.
Gastroenterology. 132:221–235. 2007.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Gasche C, Goel A, Natarajan L and Boland
CR: Mesalazine improves replication fidelity in cultured colorectal
cells. Cancer Res. 65:3993–3997. 2005.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Nandi J, Saud B, Zinkievich JM, Palma DT
and Levine RA: 5-aminosalicylic acid improves indomethacin-induced
enteropathy by inhibiting iNOS transcription in rats. Dig Dis Sci.
53:123–132. 2008.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Monteleone G, Franchi L, Fina D, Caruso R,
Vavassori P, Monteleone I, Calabrese E, Naccari GC, Bellinvia S,
Testi R and Pallone F: Silencing of SH-PTP2 defines a crucial role
in the inactivation of epidermal growth factor receptor by
5-aminosalicylic acid in colon cancer cells. Cell Death Differ.
13:202–211. 2006.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Chu EC, Chai J, Ahluwalia A and Tarnawski
AS: Mesalazine downregulates c-Myc in human colon cancer cells. A
key to its chemopreventive action? Aliment Pharmacol Ther.
25:1443–1449. 2007.PubMed/NCBI View Article : Google Scholar
|
|
68
|
Bos CL, Diks SH, Hardwick JC, Walburg KV,
Peppelenbosch MP and Richel DJ: Protein phosphatase 2A is required
for mesalazine-dependent inhibition of Wnt/beta-catenin pathway
activity. Carcinogenesis. 27:2371–2382. 2006.PubMed/NCBI View Article : Google Scholar
|
|
69
|
Stolfi C, Pellegrini R, Franze E, Pallone
F and Monteleone G: Molecular basis of the potential of mesalazine
to prevent colorectal cancer. World J Gastroenterol. 14:4434–4439.
2008.PubMed/NCBI View Article : Google Scholar
|
|
70
|
Song M, Xia B and Li J: Effects of topical
treatment of sodium butyrate and 5-aminosalicylic acid on
expression of trefoil factor 3, interleukin 1beta, and nuclear
factor kappaB in trinitrobenzene sulphonic acid induced colitis in
rats. Postgrad Med J. 82:130–135. 2006.PubMed/NCBI View Article : Google Scholar
|
|
71
|
Bersuder E, Terciolo C, Lechevrel M,
Martin E, Quesnelle C, Freund JN, Reimund JM and Gross I:
Mesalazine initiates an anti-oncogenic β-catenin/MUCDHL negative
feed-back loop in colon cancer cells by cell-specific mechanisms.
Biomed Pharmacother. 146(112543)2022.PubMed/NCBI View Article : Google Scholar
|
|
72
|
Hall DCN and Benndorf RA: Aspirin
sensitivity of PIK3CA-mutated colorectal cancer: Potential
mechanisms revisited. Cell Mol Life Sci. 79(393)2022.PubMed/NCBI View Article : Google Scholar
|
|
73
|
Bosetti C, Santucci C, Gallus S,
Martinetti M and La Vecchia C: Aspirin and the risk of colorectal
and other digestive tract cancers: An updated meta-analysis through
2019. Ann Oncol. 31:558–568. 2020.PubMed/NCBI View Article : Google Scholar
|
|
74
|
Ma J, Fan Z, Tang Q, Xia H, Zhang T and Bi
F: Aspirin attenuates YAP and β-catenin expression by promoting
β-TrCP to overcome docetaxel and vinorelbine resistance in
triple-negative breast cancer. Cell Death Dis.
11(530)2020.PubMed/NCBI View Article : Google Scholar
|
|
75
|
Newman P and Muscat J: Potential role of
non-steroidal anti-inflammatory drugs in colorectal cancer
chemoprevention for inflammatory bowel disease: An umbrella review.
Cancers (Basel). 15(1102)2023.PubMed/NCBI View Article : Google Scholar
|
|
76
|
Kohno H, Suzuki R, Sugie S and Tanaka T:
Suppression of colitis-related mouse colon carcinogenesis by a
COX-2 inhibitor and PPAR ligands. BMC Cancer. 5(46)2005.PubMed/NCBI View Article : Google Scholar
|
|
77
|
Allgayer H and Kruis W: Aminosalicylates:
Potential antineoplastic actions in colon cancer prevention. Scand
J Gastroenterol. 37:125–131. 2002.PubMed/NCBI View Article : Google Scholar
|
|
78
|
Hsiao SW, Yen HH and Chen YY:
Chemoprevention of colitis-associated dysplasia or cancer in
inflammatory bowel disease. Gut Liver. 16:840–848. 2022.PubMed/NCBI View Article : Google Scholar
|
|
79
|
Kortüm B, Radhakrishnan H, Zincke F,
Sachse C, Burock S, Keilholz U, Dahlmann M, Walther W, Dittmar G,
Kobelt D and Stein U: Combinatorial treatment with statins and
niclosamide prevents CRC dissemination by unhinging the
MACC1-β-catenin-S100A4 axis of metastasis. Oncogene. 41:4446–4458.
2022.PubMed/NCBI View Article : Google Scholar
|
|
80
|
Bassaganya-Riera J, Viladomiu M, Pedragosa
M, De Simone C and Hontecillas R: Immunoregulatory mechanisms
underlying prevention of colitis-associated colorectal cancer by
probiotic bacteria. PLoS One. 7(e34676)2012.PubMed/NCBI View Article : Google Scholar
|
|
81
|
Strehl C, Ehlers L, Gaber T and Buttgereit
F: Glucocorticoids-All-Rounders tackling the versatile players of
the immune system. Front Immunol. 10(1744)2019.PubMed/NCBI View Article : Google Scholar
|
|
82
|
An YK: Common mistakes with steroids. J
Gastroenterol Hepatol. 36 (Suppl 1):S30–S31. 2021.PubMed/NCBI View Article : Google Scholar
|
|
83
|
Lichtenstein GR, Feagan BG, Cohen RD,
Salzberg BA, Diamond RH, Price S, Langholff W, Londhe A and
Sandborn WJ: Serious infection and mortality in patients with
Crohn's disease: more than 5 years of follow-up in the TREAT™
registry. Am J Gastroenterol. 107:1409–1422. 2012.PubMed/NCBI View Article : Google Scholar
|
|
84
|
Targownik LE, Nugent Z, Singh H and
Bernstein CN: Prevalence of and outcomes associated with
corticosteroid prescription in inflammatory bowel disease. Inflamm
Bowel Dis. 20:622–630. 2014.PubMed/NCBI View Article : Google Scholar
|
|
85
|
Melmed GY, Spiegel BM, Bressler B,
Cheifetz AS, Devlin SM, Harrell LE, Irving PM, Jones J, Kaplan GG,
Kozuch PL, et al: The appropriateness of concomitant
immunomodulators with anti-tumor necrosis factor agents for Crohn's
disease: One size does not fit all. Clin Gastroenterol Hepatol.
8:655–659. 2010.PubMed/NCBI View Article : Google Scholar
|
|
86
|
Raine T and Kennedy NA: Immunomodulator
and biologic combination therapy in IBD: The debate that just won't
go away? J Crohns Colitis. 14:1343–1344. 2020.PubMed/NCBI View Article : Google Scholar
|
|
87
|
Banerjee R, Ali RAR, Wei SC and Adsul S:
Biologics for the management of inflammatory bowel disease: A
review in tuberculosis-endemic countries. Gut Liver. 14:685–698.
2020.PubMed/NCBI View Article : Google Scholar
|
|
88
|
Harris TA, Yamakuchi M, Ferlito M, Mendell
JT and Lowenstein CJ: MicroRNA-126 regulates endothelial expression
of vascular cell adhesion molecule 1. Proc Natl Acad Sci USA.
105:1516–1521. 2008.PubMed/NCBI View Article : Google Scholar
|
|
89
|
Neurath MF: Cytokines in inflammatory
bowel disease. Nat Rev Immunol. 14:329–342. 2014.PubMed/NCBI View Article : Google Scholar
|
|
90
|
Rutella S, Fiorino G, Vetrano S, Correale
C, Spinelli A, Pagano N, Arena V, Maggiano N, Repici A, Malesci A
and Danese S: Infliximab therapy inhibits inflammation-induced
angiogenesis in the mucosa of patients with Crohn's disease. Am J
Gastroenterol. 106:762–770. 2011.PubMed/NCBI View Article : Google Scholar
|
|
91
|
Günther C, Martini E, Wittkopf N, Amann K,
Weigmann B, Neumann H, Waldner MJ, Hedrick SM, Tenzer S, Neurath MF
and Becker C: Caspase-8 regulates TNF-α-induced epithelial
necroptosis and terminal ileitis. Nature. 477:335–339.
2011.PubMed/NCBI View Article : Google Scholar
|
|
92
|
Van den Brande JM, Koehler TC, Zelinkova
Z, Bennink RJ, te Velde AA, ten Cate FJ, van Deventer SJ,
Peppelenbosch MP and Hommes DW: Prediction of antitumour necrosis
factor clinical efficacy by real-time visualisation of apoptosis in
patients with Crohn's disease. Gut. 56:509–517. 2007.PubMed/NCBI View Article : Google Scholar
|
|
93
|
Chapman CG and Rubin DT: The potential for
medical therapy to reduce the risk of colorectal cancer and
optimize surveillance in inflammatory bowel disease. Gastrointest
Endosc Clin N Am. 24:353–365. 2014.PubMed/NCBI View Article : Google Scholar
|
|
94
|
Poutahidis T, Haigis KM, Rao VP, Nambiar
PR, Taylor CL, Ge Z, Watanabe K, Davidson A, Horwitz BH, Fox JG and
Erdman SE: Rapid reversal of interleukin-6-dependent epithelial
invasion in a mouse model of microbially induced colon carcinoma.
Carcinogenesis. 28:2614–2623. 2007.PubMed/NCBI View Article : Google Scholar
|
|
95
|
Kim YJ, Hong KS, Chung JW, Kim JH and Hahm
KB: Prevention of colitis-associated carcinogenesis with
infliximab. Cancer Prev Res (Phila). 3:1314–1333. 2010.PubMed/NCBI View Article : Google Scholar
|
|
96
|
Sandborn WJ, Ghosh S, Panes J, Vranic I,
Su C, Rousell S and Niezychowski W: Study A3921063 Investigators.
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative
colitis. N Engl J Med. 367:616–624. 2012.PubMed/NCBI View Article : Google Scholar
|
|
97
|
Beaugerie L, Svrcek M, Seksik P, Bouvier
AM, Simon T, Allez M, Brixi H, Gornet JM, Altwegg R, Beau P, et al:
Risk of colorectal high-grade dysplasia and cancer in a prospective
observational cohort of patients with inflammatory bowel disease.
Gastroenterology. 145:166–175.e8. 2013.PubMed/NCBI View Article : Google Scholar
|
|
98
|
Beaugerie L, Brousse N, Bouvier AM,
Colombel JF, Lémann M, Cosnes J, Hébuterne X, Cortot A, Bouhnik Y,
Gendre JP, et al: Lymphoproliferative disorders in patients
receiving thiopurines for inflammatory bowel disease: A prospective
observational cohort study. Lancet. 374:1617–1625. 2009.PubMed/NCBI View Article : Google Scholar
|
|
99
|
Zhu Z, Mei Z, Guo Y, Wang G, Wu T, Cui X,
Huang Z, Zhu Y, Wen D, Song J, et al: Reduced risk of inflammatory
bowel disease-associated colorectal neoplasia with use of
thiopurines: A systematic review and meta-analysis. J Crohns
Colitis. 12:546–558. 2018.PubMed/NCBI View Article : Google Scholar
|
|
100
|
Magro F, Gionchetti P, Eliakim R,
Ardizzone S, Armuzzi A, Barreiro-de Acosta M, Burisch J, Gecse KB,
Hart AL, Hindryckx P, et al: Third European Evidence-based
consensus on diagnosis and management of ulcerative colitis. Part
1: Definitions, diagnosis, extra-intestinal manifestations,
pregnancy, cancer surveillance, surgery, and ileo-anal pouch
disorders. J Crohns Colitis. 11:649–670. 2017.PubMed/NCBI View Article : Google Scholar
|
|
101
|
Dobrzycka M, Spychalski P, Łachiński AJ,
Kobiela P, Jędrusik P and Kobiela J: Statins and colorectal
cancer-A systematic review. Exp Clin Endocrinol Diabetes.
128:255–262. 2020.PubMed/NCBI View Article : Google Scholar
|
|
102
|
Carrat F, Seksik P, Colombel JF,
Peyrin-Biroulet L and Beaugerie L: CESAME Study Group. The effects
of aminosalicylates or thiopurines on the risk of colorectal cancer
in inflammatory bowel disease. Aliment Pharmacol Ther. 45:533–541.
2017.PubMed/NCBI View Article : Google Scholar
|
|
103
|
Qi XF, Kim DH, Yoon YS, Kim SK, Cai DQ,
Teng YC, Shim KY and Lee KJ: Involvement of oxidative stress in
simvastatin-induced apoptosis of murine CT26 colon carcinoma cells.
Toxicol Lett. 199:277–287. 2010.PubMed/NCBI View Article : Google Scholar
|
|
104
|
Bergman M, Salman H, Djaldetti M and
Bessler H: Statins as modulators of colon cancer cells induced
cytokine secretion by human PBMC. Vascul Pharmacol. 54:88–92.
2011.PubMed/NCBI View Article : Google Scholar
|
|
105
|
Ishikawa S, Hayashi H, Kinoshita K, Abe M,
Kuroki H, Tokunaga R, Tomiyasu S, Tanaka H, Sugita H, Arita T, et
al: Statins inhibit tumor progression via an enhancer of zeste
homolog 2-mediated epigenetic alteration in colorectal cancer. Int
J Cancer. 135:2528–2536. 2014.PubMed/NCBI View Article : Google Scholar
|
|
106
|
Lim T, Lee I, Kim J and Kang WK:
Synergistic effect of simvastatin plus radiation in gastric cancer
and colorectal cancer: Implications of BIRC5 and connective tissue
growth factor. Int J Radiat Oncol Biol Phys. 93:316–325.
2015.PubMed/NCBI View Article : Google Scholar
|
|
107
|
Singh S, Edakkanambeth Varayil J, Loftus
EV Jr and Talwalkar JA: Incidence of colorectal cancer after liver
transplantation for primary sclerosing cholangitis: A systematic
review and meta-analysis. Liver Transpl. 19:1361–1369.
2013.PubMed/NCBI View Article : Google Scholar
|
|
108
|
Boonstra K, Weersma RK, van Erpecum KJ,
Rauws EA, Spanier BW, Poen AC, van Nieuwkerk KM, Drenth JP,
Witteman BJ, Tuynman HA, et al: Population-based epidemiology,
malignancy risk, and outcome of primary sclerosing cholangitis.
Hepatology. 58:2045–2055. 2013.PubMed/NCBI View Article : Google Scholar
|
|
109
|
Singh S, Khanna S, Pardi DS, Loftus EV Jr
and Talwalkar JA: Effect of ursodeoxycholic acid use on the risk of
colorectal neoplasia in patients with primary sclerosing
cholangitis and inflammatory bowel disease: A systematic review and
meta-analysis. Inflamm Bowel Dis. 19:1631–1638. 2013.PubMed/NCBI View Article : Google Scholar
|
|
110
|
Nagengast FM, Grubben MJ and van Munster
IP: Role of bile acids in colorectal carcinogenesis. Eur J Cancer.
31A:1067–1070. 1995.PubMed/NCBI View Article : Google Scholar
|
|
111
|
Potack J and Itzkowitz SH: Colorectal
cancer in inflammatory bowel disease. Gut Liver. 2:61–73.
2008.PubMed/NCBI View Article : Google Scholar
|
|
112
|
Swinson CM, Perry J, Lumb M and Levi AJ:
Role of sulphasalazine in the aetiology of folate deficiency in
ulcerative colitis. Gut. 22:456–461. 1981.PubMed/NCBI View Article : Google Scholar
|
|
113
|
Ditonno I, Novielli D, Celiberto F, Rizzi
S, Rendina M, Ierardi E, Di Leo A and Losurdo G: Molecular pathways
of carcinogenesis in familial adenomatous polyposis. Int J Mol Sci.
24(5687)2023.PubMed/NCBI View Article : Google Scholar
|
|
114
|
Mao R, Krautscheid P, Graham RP, Ganguly
A, Shankar S, Ferber M and Hegde M: ACMG Laboratory Quality
Assurance Committee. Genetic testing for inherited colorectal
cancer and polyposis, 2021 revision: A technical standard of the
American College of Medical Genetics and Genomics (ACMG). Genet
Med. 23:1807–1817. 2021.PubMed/NCBI View Article : Google Scholar
|
|
115
|
Bhattacharya P and McHugh TW: Lynch
Syndrome. In: StatPearls [Internet]. StatPearls Publishing,
Treasure Island, FL, 2023.
|
|
116
|
Cohen PR and Kurzrock R: Germline testing
of mismatch repair genes is needed in the initial evaluation of
patients with muir-torre syndrome-associated cutaneous sebaceous
neoplasms: A case series. Cureus. 15(e33975)2023.PubMed/NCBI View Article : Google Scholar
|
|
117
|
Park SY, Kim KS and Min HJ: Peutz-Jeghers
syndrome and sinonasal diseases: A case report and literature
review. Ear Nose Throat J: Sep 19, 2022 (Epub ahead of print).
|
|
118
|
Garofola C, Jamal Z and Gross GP: Cowden
Disease. In: StatPearls [Internet]. StatPearls Publishing, Treasure
Island, FL, 2023.
|
|
119
|
Dal Buono A, Gaiani F, Poliani L and Laghi
L: Juvenile polyposis syndrome: An overview. Best Pract Res Clin
Gastroenterol. 58-59(101799)2022.PubMed/NCBI View Article : Google Scholar
|
|
120
|
Soares de Lima Y, Arnau-Collell C, Muñoz
J, Herrera-Pariente C, Moreira L, Ocaña T, Díaz-Gay M,
Franch-Expósito S, Cuatrecasas M, Carballal S, et al: Germline
mutations in WNK2 could be associated with serrated polyposis
syndrome. J Med Genet. 60:557–567. 2023.PubMed/NCBI View Article : Google Scholar
|
|
121
|
Ahmed M: Colon cancer: A clinician's
perspective in 2019. Gastroenterology Res. 13:1–10. 2020.PubMed/NCBI View Article : Google Scholar
|
|
122
|
Burnett-Hartman AN, Lee JK, Demb J and
Gupta S: An update on the epidemiology, molecular characterization,
diagnosis, and screening strategies for early-onset colorectal
cancer. Gastroenterology. 160:1041–1049. 2021.PubMed/NCBI View Article : Google Scholar
|
